Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Probiotics | Research

The effects of soymilk plus probiotics supplementation on cardiovascular risk factors in patients with type 2 diabetes mellitus: a randomized clinical trial

Authors: Azimeh Hasanpour, Siavash Babajafari, Seyed Mohammad Mazloomi, Mesbah Shams

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Objective

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular diseases. This study aimed to assess the effects of soymilk plus probiotics co-administration on cardiovascular risk factors in T2DM patients.

Methods

One hundred patients with T2DM (aged 40–75 years old) were randomly assigned into 4 groups (soymilk + probiotics supplement, soymilk + placebo, conventional milk + placebo, and probiotics supplement) for 6 weeks. Standard protocols were followed for the collection of fasting blood samples, dietary intakes, and anthropometric measurements.

Results

It was shown that soymilk + probiotics consumption significantly decreased diastolic blood pressure (DBP) (p = 0.001), triglycerides (TG) (P < 0.001), total cholesterol (TC) (p < 0.01), and insulin (P < 0.003) levels and significantly increased high-density lipoprotein cholesterol (HDL-C) (P = 0.002) levels. Soymilk + placebo administration significantly decreased DBP (p = 0.01), insulin (p = 0.006), and TG (p = 0.001) levels and significantly increased HDL-C (p = 0.03) levels. A significant decrease in insulin (p = 0.003) and systolic blood pressure (SBP) (p = 0.01) levels and an increase in HDL-C (p = 0.04) levels were observed after supplementation with probiotics. Findings from between-group comparisons showed a significant decrease in SBP levels in the probiotics supplement group compared to conventional milk group (p < 0.05).

Conclusion

Soymilk and probiotics consumption might improve some cardiovascular risk factors in patients with T2DM. However, possible synergic effects while consumption of soymilk plus probiotics supplement didn’t show in this study which warranted further research.
Literature
1.
go back to reference Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 Diabetes Mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022;77(3):444–54.CrossRefPubMed Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 Diabetes Mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022;77(3):444–54.CrossRefPubMed
2.
go back to reference Green JB. Novel treatment advances and approaches in the management of type 2 diabetes: a closer look at the evolving role of SGLT2 inhibitors. Millions of patients treated as individuals. 2021:67. Green JB. Novel treatment advances and approaches in the management of type 2 diabetes: a closer look at the evolving role of SGLT2 inhibitors. Millions of patients treated as individuals. 2021:67.
3.
go back to reference Kootte R, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(2):112–20.CrossRefPubMed Kootte R, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(2):112–20.CrossRefPubMed
5.
go back to reference Ziemer CJ, Gibson GR. An overview of probiotics, prebiotics and synbiotics in the functional food concept: perspectives and future strategies. Int Dairy J. 1998;8(5):473–9.CrossRef Ziemer CJ, Gibson GR. An overview of probiotics, prebiotics and synbiotics in the functional food concept: perspectives and future strategies. Int Dairy J. 1998;8(5):473–9.CrossRef
6.
go back to reference Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94(7):3288–94.CrossRefPubMed Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94(7):3288–94.CrossRefPubMed
7.
go back to reference Pegah A, Abbasi-Oshaghi E, Khodadadi I, Mirzaei F, Tayebinia H. Probiotic and resveratrol normalize GLP-1 levels and oxidative stress in the intestine of diabetic rats. Metabolism Open. 2021;10: 100093.CrossRefPubMedPubMedCentral Pegah A, Abbasi-Oshaghi E, Khodadadi I, Mirzaei F, Tayebinia H. Probiotic and resveratrol normalize GLP-1 levels and oxidative stress in the intestine of diabetic rats. Metabolism Open. 2021;10: 100093.CrossRefPubMedPubMedCentral
8.
go back to reference Xiao R, Wang R, Li S, Kang X, Ren Y, Sun E, et al. Preliminary evaluation of potential properties of three probiotics and their combination with prebiotics on GLP-1 secretion and type 2 diabetes alleviation. J Food Qual. 2022;2022. Xiao R, Wang R, Li S, Kang X, Ren Y, Sun E, et al. Preliminary evaluation of potential properties of three probiotics and their combination with prebiotics on GLP-1 secretion and type 2 diabetes alleviation. J Food Qual. 2022;2022.
9.
go back to reference Zhai L, Wu J, Lam YY, Kwan HY, Bian Z-X, Wong HLX. Gut-microbial metabolites, probiotics and their roles in type 2 diabetes. Int J Mol Sci. 2021;22(23):12846.CrossRefPubMedPubMedCentral Zhai L, Wu J, Lam YY, Kwan HY, Bian Z-X, Wong HLX. Gut-microbial metabolites, probiotics and their roles in type 2 diabetes. Int J Mol Sci. 2021;22(23):12846.CrossRefPubMedPubMedCentral
10.
go back to reference Zhang C, Wang C, Li S, Yu L, Tian F, Zhao J, et al. Meta-analysis of randomized controlled trials of the effects of probiotics on type 2 diabetes in adults. Clin Nutr. 2022;41(2):365–73.CrossRefPubMed Zhang C, Wang C, Li S, Yu L, Tian F, Zhao J, et al. Meta-analysis of randomized controlled trials of the effects of probiotics on type 2 diabetes in adults. Clin Nutr. 2022;41(2):365–73.CrossRefPubMed
11.
go back to reference Bock PM, Telo GH, Ramalho R, Sbaraini M, Leivas G, Martins AF, et al. The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2021;64(1):26–41.CrossRefPubMed Bock PM, Telo GH, Ramalho R, Sbaraini M, Leivas G, Martins AF, et al. The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2021;64(1):26–41.CrossRefPubMed
12.
go back to reference Setchell K. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998;68(6):1333S-S1346.CrossRefPubMed Setchell K. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998;68(6):1333S-S1346.CrossRefPubMed
13.
go back to reference Anderson JW, Smith BM, Washnock CS. Cardiovascular and renal benefits of dry bean and soybean intake. Am J Clin Nutr. 1999;70(3):464s-s474.CrossRefPubMed Anderson JW, Smith BM, Washnock CS. Cardiovascular and renal benefits of dry bean and soybean intake. Am J Clin Nutr. 1999;70(3):464s-s474.CrossRefPubMed
14.
15.
go back to reference Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence 1. J Clin Endocrinol Metab. 1998;83(7):2223–35.PubMed Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence 1. J Clin Endocrinol Metab. 1998;83(7):2223–35.PubMed
16.
go back to reference Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol. 2000;35(6):1403–10.CrossRefPubMed Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol. 2000;35(6):1403–10.CrossRefPubMed
17.
go back to reference Velasquez MT, Bhathena SJ. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis. 2001;37(5):1056–68.CrossRefPubMed Velasquez MT, Bhathena SJ. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis. 2001;37(5):1056–68.CrossRefPubMed
18.
go back to reference Li W, Ruan W, Peng Y, Wang D. Soy and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Diabetes Res Clin Pract. 2018;137:190–9.CrossRefPubMed Li W, Ruan W, Peng Y, Wang D. Soy and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Diabetes Res Clin Pract. 2018;137:190–9.CrossRefPubMed
19.
go back to reference Asbaghi O, Ashtary-Larky D, Mousa A, RezaeiKelishadi M, Moosavian SP. The effects of soy products on cardiovascular risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of clinical trials. Adv Nutr. 2022;13(2):455–73.CrossRef Asbaghi O, Ashtary-Larky D, Mousa A, RezaeiKelishadi M, Moosavian SP. The effects of soy products on cardiovascular risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of clinical trials. Adv Nutr. 2022;13(2):455–73.CrossRef
20.
go back to reference Yang A, Smyth H, Chaliha M, James A. Sensory quality of soymilk and tofu from soybeans lacking lipoxygenases. Food Sci Nutr. 2016;4(2):207–15.CrossRefPubMed Yang A, Smyth H, Chaliha M, James A. Sensory quality of soymilk and tofu from soybeans lacking lipoxygenases. Food Sci Nutr. 2016;4(2):207–15.CrossRefPubMed
21.
go back to reference Abbasi B, Mirlohi M, Daniali M, Ghiasvand R. Effects of probiotic soymilk on lipid panel in type 2 diabetic patients with nephropathy: a double-blind randomized clinical trial. Prog Nutr. 2018;20:70–8. Abbasi B, Mirlohi M, Daniali M, Ghiasvand R. Effects of probiotic soymilk on lipid panel in type 2 diabetic patients with nephropathy: a double-blind randomized clinical trial. Prog Nutr. 2018;20:70–8.
22.
go back to reference Mohammadi Sartang M, Mazloomi SM, Tanideh N, Rezaian Zadeh A. The effects of probiotic soymilk fortified with omega-3 on blood glucose, lipid profile, hematological and oxidative stress, and inflammatory parameters in streptozotocin nicotinamide-induced diabetic rats. J Diabetes Res. 2015;2015. Mohammadi Sartang M, Mazloomi SM, Tanideh N, Rezaian Zadeh A. The effects of probiotic soymilk fortified with omega-3 on blood glucose, lipid profile, hematological and oxidative stress, and inflammatory parameters in streptozotocin nicotinamide-induced diabetic rats. J Diabetes Res. 2015;2015.
23.
go back to reference Hariri M, Salehi R, Feizi A, Mirlohi M, Kamali S, Ghiasvand R. The effect of probiotic soy milk and soy milk on anthropometric measures and blood pressure in patients with type II diabetes mellitus: a randomized double-blind clinical trial. ARYA atherosclerosis. 2015;11(Suppl 1):74.PubMedPubMedCentral Hariri M, Salehi R, Feizi A, Mirlohi M, Kamali S, Ghiasvand R. The effect of probiotic soy milk and soy milk on anthropometric measures and blood pressure in patients with type II diabetes mellitus: a randomized double-blind clinical trial. ARYA atherosclerosis. 2015;11(Suppl 1):74.PubMedPubMedCentral
24.
go back to reference Feizollahzadeh S, Ghiasvand R, Rezaei A, Khanahmad H, Hariri M. Effect of probiotic soy milk on serum levels of adiponectin, inflammatory mediators, lipid profile, and fasting blood glucose among patients with type II diabetes mellitus. Probiotics and antimicrobial proteins. 2017;9(1):41–7.CrossRefPubMed Feizollahzadeh S, Ghiasvand R, Rezaei A, Khanahmad H, Hariri M. Effect of probiotic soy milk on serum levels of adiponectin, inflammatory mediators, lipid profile, and fasting blood glucose among patients with type II diabetes mellitus. Probiotics and antimicrobial proteins. 2017;9(1):41–7.CrossRefPubMed
25.
go back to reference de Pascual-Teresa S, Hallund J, Talbot D, Schroot J, Williams CM, Bugel S, et al. Absorption of isoflavones in humans: effects of food matrix and processing. J Nutr Biochem. 2006;17(4):257–64.CrossRefPubMed de Pascual-Teresa S, Hallund J, Talbot D, Schroot J, Williams CM, Bugel S, et al. Absorption of isoflavones in humans: effects of food matrix and processing. J Nutr Biochem. 2006;17(4):257–64.CrossRefPubMed
26.
go back to reference Franke AA, Custer LJ, Hundahl SA. Determinants for urinary and plasma isoflavones in humans after soy intake. Nutr Cancer. 2004;50(2):141–54.CrossRefPubMed Franke AA, Custer LJ, Hundahl SA. Determinants for urinary and plasma isoflavones in humans after soy intake. Nutr Cancer. 2004;50(2):141–54.CrossRefPubMed
27.
go back to reference Franke AA, Ashburn LA, Kakazu K, Suzuki S, Wilkens LR, Halm BM. Apparent bioavailability of isoflavones after intake of liquid and solid soya foods. Br J Nutr. 2009;102(8):1203–10.CrossRefPubMedPubMedCentral Franke AA, Ashburn LA, Kakazu K, Suzuki S, Wilkens LR, Halm BM. Apparent bioavailability of isoflavones after intake of liquid and solid soya foods. Br J Nutr. 2009;102(8):1203–10.CrossRefPubMedPubMedCentral
28.
go back to reference Ali AA, Velasquez MT, Hansen CT, Mohamed AI, Bhathena SJ. Effects of soybean isoflavones, probiotics, and their interactions on lipid metabolism and endocrine system in an animal model of obesity and diabetes. J Nutr Biochem. 2004;15(10):583–90.CrossRefPubMed Ali AA, Velasquez MT, Hansen CT, Mohamed AI, Bhathena SJ. Effects of soybean isoflavones, probiotics, and their interactions on lipid metabolism and endocrine system in an animal model of obesity and diabetes. J Nutr Biochem. 2004;15(10):583–90.CrossRefPubMed
29.
go back to reference Golubic R, May AM, Benjaminsen Borch K, Overvad K, Charles M-A, Diaz MJT, et al. Validity of electronically administered Recent Physical Activity Questionnaire (RPAQ) in ten European countries. PLoS ONE. 2014;9(3): e92829.CrossRefPubMedPubMedCentral Golubic R, May AM, Benjaminsen Borch K, Overvad K, Charles M-A, Diaz MJT, et al. Validity of electronically administered Recent Physical Activity Questionnaire (RPAQ) in ten European countries. PLoS ONE. 2014;9(3): e92829.CrossRefPubMedPubMedCentral
30.
go back to reference Miraghajani M, Mortazavi Najafabadi M, Emaillzadeh A, Mirlohi M, Azadbakht L. Effects of soy milk consumption on cardiovascular risk factors and renal function among type 2 diabetic patients with nephropathy. J Health Syst Res. 2012;7(6):935–48. Miraghajani M, Mortazavi Najafabadi M, Emaillzadeh A, Mirlohi M, Azadbakht L. Effects of soy milk consumption on cardiovascular risk factors and renal function among type 2 diabetic patients with nephropathy. J Health Syst Res. 2012;7(6):935–48.
31.
go back to reference Moroti C, Souza Magri LF, de Rezende CM, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012;11(1):1–8.CrossRef Moroti C, Souza Magri LF, de Rezende CM, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012;11(1):1–8.CrossRef
32.
go back to reference Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran lipid and glucose study. Acta Diabetol. 2015;52(5):905–15.CrossRefPubMed Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran lipid and glucose study. Acta Diabetol. 2015;52(5):905–15.CrossRefPubMed
33.
go back to reference Sohouli MH, Lari A, Fatahi S, Shidfar F, Găman M-A, Guimaraes NS, et al. Impact of soy milk consumption on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials. Journal of Functional Foods. 2021;83: 104499.CrossRef Sohouli MH, Lari A, Fatahi S, Shidfar F, Găman M-A, Guimaraes NS, et al. Impact of soy milk consumption on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials. Journal of Functional Foods. 2021;83: 104499.CrossRef
34.
go back to reference Miraghajani MS, Najafabadi MM, Surkan PJ, Esmaillzadeh A, Mirlohi M, Azadbakht L. Soy milk consumption and blood pressure among type 2 diabetic patients with nephropathy. J Ren Nutr. 2013;23(4):277-82 e1.CrossRefPubMed Miraghajani MS, Najafabadi MM, Surkan PJ, Esmaillzadeh A, Mirlohi M, Azadbakht L. Soy milk consumption and blood pressure among type 2 diabetic patients with nephropathy. J Ren Nutr. 2013;23(4):277-82 e1.CrossRefPubMed
35.
go back to reference Akhlaghi M, Zare M, Nouripour F. Effect of soy and soy isoflavones on obesity-related anthropometric measures: a systematic review and meta-analysis of randomized controlled clinical trials. Adv Nutr. 2017;8(5):705–17.CrossRefPubMedPubMedCentral Akhlaghi M, Zare M, Nouripour F. Effect of soy and soy isoflavones on obesity-related anthropometric measures: a systematic review and meta-analysis of randomized controlled clinical trials. Adv Nutr. 2017;8(5):705–17.CrossRefPubMedPubMedCentral
36.
go back to reference Liang T, Wu L, Xi Y, Li Y, Xie X, Fan C, et al. Probiotics supplementation improves hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes mellitus: an update of meta-analysis. Crit Rev Food Sci Nutr. 2021;61(10):1670–88.CrossRefPubMed Liang T, Wu L, Xi Y, Li Y, Xie X, Fan C, et al. Probiotics supplementation improves hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes mellitus: an update of meta-analysis. Crit Rev Food Sci Nutr. 2021;61(10):1670–88.CrossRefPubMed
37.
go back to reference Miraghajani M, Zaghian N, Mirlohi M, Feizi A, Ghiasvand R. The impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: a randomized controlled clinical trial. J Ren Nutr. 2017;27(5):317–24.CrossRefPubMed Miraghajani M, Zaghian N, Mirlohi M, Feizi A, Ghiasvand R. The impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: a randomized controlled clinical trial. J Ren Nutr. 2017;27(5):317–24.CrossRefPubMed
38.
go back to reference Jung S, Sirirat R, Kim A, Amen R, Kaur A, Ianchis A, et al. The effect of a fermented soy-based dietary food product on blood lipids in individuals at high risk for cardiovascular disease. Curr Dev Nutr. 2020;4(Supplement_2):409.CrossRefPubMedCentral Jung S, Sirirat R, Kim A, Amen R, Kaur A, Ianchis A, et al. The effect of a fermented soy-based dietary food product on blood lipids in individuals at high risk for cardiovascular disease. Curr Dev Nutr. 2020;4(Supplement_2):409.CrossRefPubMedCentral
39.
go back to reference Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333(5):276–82.CrossRefPubMed Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333(5):276–82.CrossRefPubMed
40.
go back to reference Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW Jr, Hasler CM. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr. 2000;71(5):1077–84.CrossRefPubMed Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW Jr, Hasler CM. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr. 2000;71(5):1077–84.CrossRefPubMed
41.
go back to reference Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate. 2009;69(7):719–26.CrossRefPubMedPubMedCentral Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate. 2009;69(7):719–26.CrossRefPubMedPubMedCentral
42.
go back to reference Kano M, Takayanagi T, Harada K, Sawada S, Ishikawa F. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr. 2006;136(9):2291–6.CrossRefPubMed Kano M, Takayanagi T, Harada K, Sawada S, Ishikawa F. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr. 2006;136(9):2291–6.CrossRefPubMed
43.
go back to reference Nielsen ILF, Williamson G. Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr Cancer. 2007;57(1):1–10.CrossRefPubMed Nielsen ILF, Williamson G. Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr Cancer. 2007;57(1):1–10.CrossRefPubMed
Metadata
Title
The effects of soymilk plus probiotics supplementation on cardiovascular risk factors in patients with type 2 diabetes mellitus: a randomized clinical trial
Authors
Azimeh Hasanpour
Siavash Babajafari
Seyed Mohammad Mazloomi
Mesbah Shams
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01290-w

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine